Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

TOT Biopharm (东曜药业) IPO: Valuation of Core Product TAB008, a Bevacizumab Biosimilar

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

TOT Biopharm International / Equity Capital Markets

<p>TOT Biopharm, a China-based clinical-stage biopharmaceutical company, plans to raise at least USD 100 million from its listing on the Hong Kong Stock Exchange. In this insight, we will look at the company's product pipeline, and the company's shareholders and management team. </p>
<p>With only one Avastin biosimilar in the near-commercial stage clinical trial, we think the company's portfolio and the experience of the management team are not impressive. </p>

TOT Biopharm, a China-based clinical-stage biopharmaceutical company, plans to raise at least USD 100 million from its listing on the Hong Kong Stock Exchange. In this insight, we will look at the company's product pipeline, and the company's shareholders and management team. 
With only one Avastin biosimilar in the near-commercial stage clinical trial, we think the company's portfolio and the experience of the management team are not impressive. 

TOT Biopharm (东曜药业) IPO: An Unimpressive Pipeline